Med. praxi. 2023;20(3):157-162 | DOI: 10.36290/med.2023.024

Climacteric patient in office of general practitioner

doc. MUDr. Tomáš Fait, Ph.D.
Gynekologicko-porodnická klinika 2. LF UK a FN Motol, Praha
Katedra zdravotnických studií, Vysoká škola polytechnická Jihlava

Hormone replacement therapy (HRT) is the most effective treatment for acute climacteric syndrome and has been proven to prevent bone loss and fractures. In women within 10 years of the onset of menopause it is prevention of atherosclerosis and dementia. Later initiation of treatment is on opposite side connected with the worsening of these processes. We prefer the lowest doses of estrogen and natural type of gestagen for higher safety especially from the breast cacer risk point of view. For women which prefer nonhormonal therapy we have broad offer of alternative medicine. Some of them have scientific confirmation of safety and efficacy (DT56a soya bean extract, PI82/GC Fem polen extract).

Keywords: hormone replacement therapy, acute climacteric syndrome, fytoestrogene, polen extracts.

Accepted: June 9, 2023; Published: June 15, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Fait T. Climacteric patient in office of general practitioner. Med. praxi. 2023;20(3):157-162. doi: 10.36290/med.2023.024.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. NAMS Position Statement: The 2022 Hormone Therapy Position Statement. Menopause. 2022;29(7):767-94. Go to original source... Go to PubMed...
    2. Fait T. Hormone replacement therapy: latest developments and clinical practice. Drugs in Context. 2019;8:212551. Go to original source... Go to PubMed...
    3. Santoro N, Epperson CN, Mathews SB. Menopausal symptoms and their management. Endocrinol Metab Clin North Am. 2015;44:497-515. Go to original source... Go to PubMed...
    4. Biglia N, Cagnacci A, Gambacciani M, et al. Vasomotor symptoms in menopause: a biomarker of cardiovascular disease risk and other chronic diseases? Climacteric 2017;20(4):306-12. Go to original source... Go to PubMed...
    5. Thurston R, Chang Y, Barinas-Mitchel E, et al. Physiologically assessed hot flashes and endothelial function among midlife women. Menopause. 2017;24(8):886-93. Go to original source... Go to PubMed...
    6. Herber-Gast B, Brown WJ, Mishra GD. Hot flushes and night sweats are associated with coronary heart disease risk in midlife: a longitudinal study. BJOG 2015;122:1560-7. Go to original source... Go to PubMed...
    7. Thurston RC, Aizenstein HJ, Derby CA, et al. Menopausal hot flashes and white matter hyperintensities. Menopause. 2016;23:27-32. Go to original source... Go to PubMed...
    8. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998 Aug 19;280(7):605-13. doi: 10.1001/jama.280.7.605. PMID: 9718051. Go to original source... Go to PubMed...
    9. Koire A, Joffe H, Buckley R. Replacement in the Prevention and Treatment of Cognitive Decline, Dementia, and Cognitive Dysfunction of Depression. Harv Rev Psychiatry. 2022; 30(4):215-22. Go to original source... Go to PubMed...
    10. Kim J, Chang JH, Jeong MJ, et al. A systematic review and metaanalysis of effects of menopause hormone therapy on cardiovascular diseases. Sci Rep. 2020;10(1):20631. Go to original source... Go to PubMed...
    11. Fait T, Vrablik M. Coronary heart disease and hormone replacement therapy - from primary and secondary prevention to the window of opportunity. Neuro Endocrinol Lett. 2012;33(Suppl. 2):17-21. Go to PubMed...
    12. Fait T. Klíč k nasazení HRT. Gynek Porod. 2020;4(3):133-6.
    13. Panay N, Anderson RA, Nappi RE, et al. Premature ovarian insufficiency: an International Menopause Society White Paper. Climacteric. 2020;23(5):426-46. Go to original source... Go to PubMed...
    14. Tan DA, Dayu ARB. Menopausal hormone therapy: why we should no longer be afraid of the breast cancer risk. Climacteric. 2022;25(4):362-8. Go to original source... Go to PubMed...
    15. Ruan X, Mueck AO. Primary choice of estrogen and progesteron as components of HRT. Climacteric. 2022;25(5):443-52. Go to original source... Go to PubMed...
    16. Fournier A, Berino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat. 2008;107(1):103-11. Go to original source... Go to PubMed...
    17. Fait T. Tibolon - jediný zástupce skupiny STEARs. Cas Lek Ces. 2019;158:107-111.
    18. Scarabin PY, Oger E, Plu-Bureau G; EStrogen and THromboEmbolism Risk Study Group. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet. 2003 Aug 9;362(9382):428-32. doi: 10.1016/S0140-6736(03)14066-4. PMID: 12927428. Go to original source... Go to PubMed...
    19. Crandall CJ, Mehta JM, Manson JE. Management of menopausal symptoms: a review. JAMA. 2023;329(5):405-20. Go to original source... Go to PubMed...
    20. Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women´s Health Initiative randomized trial. JAMA. 2003;290(13):1729-38. Go to original source... Go to PubMed...
    21. Robbins JA, Argaki A, Crandall CJ, et al. WHI trials: interaction of calcium and vitamin D with hormone therapy. Menopause. 2014;21(2):116-23. Go to original source... Go to PubMed...
    22. Torgerson DJ, Bell-Syer SEM. Hormone replacement therapy and prevention of nonvertebral fracture: a meta-analysis of randomized trials. JAMA. 2001;285(22):2891-7. Go to original source... Go to PubMed...
    23. Zhu L, Jiang X, Sun Y, et al. Effect of hormone therapy on the risk of bone fractures: a systematic review and meta-analysis of randomized controlled trials. Menopause. 2016;23(4):461-70. Go to original source... Go to PubMed...
    24. NAMS Management of symptomatic vulvovaginal atrophy, position statement of the North American Menopause Society. Menopause. 2013;20:888-902. Go to PubMed...
    25. Ulrich LSG, Naessen T, Elia D, et al. Endometrial safety of ultra-low-dose Vagifem 10 μg in postmenopausal women with vaginal atrophy. Climacteric 2010;1:228-237. Go to original source... Go to PubMed...
    26. Sirotkin AV, Harrath AH. Phytoestrogens and their effects. Eur J Pharmacol. 2014;741:230-6. Go to original source... Go to PubMed...
    27. Duncan AM, Phipps WR, Kurzer MS. Phyto-estrogens. Best Practice Research Clin Endocrin Metab. 2003;17(2):253-71. Go to original source... Go to PubMed...
    28. Ye YB, Tang XY, Verbruggen M, Su YX. Soy isoflavones attenuate bone loss in early postmenopausal Chinese women. Eur J Nutr. 2006;3:1-8. Go to original source... Go to PubMed...
    29. Atkinson C, Newton KM, Bowless EJ, et al. Demographic, anthropometric, and lifestyle factors and dietary intakes in relation to daidzein-metabolizing phenotypes among premenopausal women in USA. Am J Clin Nutr. 2008;87:679-87. Go to original source... Go to PubMed...
    30. Labos G, Trakakis E, Pliatsika P, et al. Efficacy and safety of DT56a (Femarelle) compared to hormone therapy in Greek postmenopausal women. J Endocrinol Invest. 2013;36:521-6. Go to PubMed...
    31. Sánchez-Borrego R, Mendoza N, Llaneza P. A prospective study of DT56a (Femarelle®) for the treatment of menopause symptoms. Climacteric. 2015;10:1-8. Go to original source... Go to PubMed...
    32. Fait T, Borovsky M. DT56a in treatment of climacteric syndrome in a Central European population sample. Bratislava Medical Journal. 2021;122(5):301-4. Go to original source... Go to PubMed...
    33. Hellström AC, Muntzing J. The pollen extract Femal - a nonestrogenic alternative to hormone therapy in women with menopausal symptoms. Menopause. 2012;19(7):825-9. Go to original source... Go to PubMed...
    34. Fait T, Sailer M, Regidor PA. Prospective observational study to evaluate the efficacy and safety of the pollen extract Sérélys® in the management of women with menopausal symptoms. Gynecol Endocrinol. 2019;35(4):360-3. Go to original source... Go to PubMed...
    35. Llaneza P, Garcia-Portilla P, Llaneza-Suarez D, et al. Depressive disorders and the menopause transition. Maturitas. 2012;71:120-30. Go to original source... Go to PubMed...
    36. Toffol E, Kekinheimo O, Patronen T. Hormone therapy and mood in in perimenopausal women. Menopause. 2015;22(5):564-78. Go to original source... Go to PubMed...
    37. Liu T, Chen S, Milke GI, et al. Effects of exercise on vasomotor symptoms in menopausal women: a systematic review and meta-analysis. Climacteric. 2022;29:1-10. Go to original source... Go to PubMed...

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.